Table 1 Definitions of the values used for the calculation and, where relevant, the ranges of values used for the sensitivity analysis.
From: Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
Definition | Symbol | Value | Lower | Upper | Source |
|---|---|---|---|---|---|
The proportion of the population expected to be exposed from July to December 2020 | α | 0.07 | 0.05 | 0.15 | [9] |
Level of access to appropriate respiratory support (as a proportion) | κ | 1 | 0.5 | 1 | – |
Increase in fatality rate if no access to appropriate respiratory support | ψ | 1 | 1 | 2 | – |
Probability of hospitalised patient needing oxygen (either non-invasive or ventilator) | \(p_{O_2}\) | 0.76 | 0.2 | 0.9 | [4] |
Probability of a hospitalised patient who receives oxygen needing a ventilator if on dexamethasone | pVd | 0.22*0.87 | 0.04 | 0.5 | [4] |
Probability of an infected patient who receives oxygen needing a ventilator if not on dexamethasone | pV | 0.22 | 0.05 | 0.6 | [4] |
Maximum death probability for a hospitalised infection | δH | 0.3 | – | – | [2] |
Maximum death probability for a hospitalised infection requiring non-invasive oxygen | \(\delta _{O_2}\) | 0.4 | – | – | [2] |
Maximum death probability for a hospitalised infection requiring a ventilator | δV | 0.66 | – | – | [2] |
Reduction in mortality for patients requiring non-invasive oxygen if on dexamethasone | \({\it{\epsilon }}_{O_2}\) | 0.2 | – | – | [4] |
Reduction in mortality for patients requiring a ventilator if on dexamethasone | ϵV | 0.36 | – | – | [4] |
Incremental number of days spent in a general ward bed for a survivor that required non-invasive oxygen | \({\mathrm{ids}}_{\mathrm{o}_2}\) | 4.5 | 2 | 7 | [20] |
Incremental number of days spent in a general ward bed for a survivor that required ventilation | idsv | 5 | 3 | 8 | [20] |
Incremental number of days spent in an ICU bed for a survivor that required ventilation | idcv | −1 | −2 | 3 | [20] |
